Table 1 Baseline characteristics of study groups.
Topical gentamicin (N = 74) | Topical saline solution (N = 72) | p-value | |
|---|---|---|---|
Age, Mean ± SD | 67.2 ± 11.31 | 65.36 ± 14.08 | 0.384 |
Sex, N (%) | 0.517 | ||
Male | 31 (41.9) | 34 (47.2) | |
Female | 43 (58.1) | 38 (52.8) | |
BMI (Kg/m2), Mean ± SD | 30.29 ± 5.74 | 30.12 ± 5.04 | 0.84 |
Comorbidities, N (%) | |||
Diabetes mellitus | 13 (17.6) | 10 (13.9) | 0.542 |
Heart disease | 13 (17.6) | 10 (13.9) | 0.542 |
Chronic pulmonary disease | 9 (12.2) | 8 (11.1) | 0.843 |
Renal disease | 0 | 3 (4.2) | 0.117 |
Liver disease | 2 (2.7) | 0 | 0.497 |
Obesity | 37 (50) | 38 (52.8) | 0.037 |
Tobacco use | 9 (12.2) | 8 (11.1) | 0.843 |
Steroid or immunosuppressant use | 2 (2.7) | 3 (4.2) | 0.679 |
ASA, N (%) | 0.377 | ||
ASA I | 4 (5.4) | 6 (8.3) | 0.53 |
ASA II | 57 (77) | 48 (66.7) | 0.164 |
ASA III | 13 (17.6) | 18 (25) | 0.272 |
Recurrent hernia, N (%) | 16 (21.6) | 18 (25) | 0.629 |
